NPI: 1700228418 · SHELBY, NC 28150 · Registered Dietitian · NPI assigned 07/23/2013
Authorized official RISSMILLER, SCOTT controls 20+ related entities in our dataset. Read more
| Authorized Official | RISSMILLER, SCOTT (ENTERPRISE EVP) |
| Parent Organization | CAROLINAS PHYSICIANS NETWORK INC |
| NPI Enumeration Date | 07/23/2013 |
Other providers sharing the same authorized official: RISSMILLER, SCOTT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 98,245 | $3.07M |
| 2019 | 105,726 | $3.98M |
| 2020 | 93,566 | $3.24M |
| 2021 | 208,200 | $4.60M |
| 2022 | 312,234 | $5.13M |
| 2023 | 346,752 | $5.05M |
| 2024 | 360,467 | $4.57M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 119,753 | 104,295 | $7.27M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 68,697 | 61,216 | $6.21M |
| 99199 | Unlisted special service, procedure or report | 672,529 | 429,785 | $3.58M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 31,393 | 25,680 | $2.68M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 26,721 | 22,206 | $2.33M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 16,739 | 14,951 | $1.53M |
| 90472 | Immunization administration, each additional vaccine (list separately) | 29,918 | 25,116 | $873K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 47,698 | 40,942 | $861K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 17,633 | 15,687 | $830K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 7,549 | 6,554 | $741K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 9,338 | 8,577 | $564K |
| 85027 | 56,594 | 49,425 | $408K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 42,355 | 36,258 | $194K |
| 54150 | 1,218 | 1,006 | $170K | |
| 99215 | Prolong outpt/office vis | 1,301 | 1,174 | $163K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3,455 | 2,945 | $153K |
| 96127 | 32,775 | 29,189 | $126K | |
| 90474 | 6,800 | 5,776 | $121K | |
| D0145 | Oral evaluation for a patient under three years of age | 3,143 | 2,768 | $100K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2,908 | 2,685 | $76K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5,822 | 5,283 | $75K |
| 83655 | 5,241 | 4,583 | $71K | |
| 99051 | 2,122 | 2,036 | $51K | |
| D1206 | Topical application of fluoride varnish | 3,128 | 2,752 | $44K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1,068 | 891 | $39K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2,104 | 1,236 | $27K |
| 92551 | 36,735 | 32,663 | $26K | |
| 0071A | 567 | 365 | $24K | |
| 99422 | 813 | 463 | $22K | |
| 0001A | 508 | 325 | $21K | |
| 0072A | 462 | 313 | $20K | |
| 90677 | 2,571 | 2,483 | $19K | |
| 90651 | 2,362 | 2,101 | $19K | |
| 0002A | 342 | 268 | $17K | |
| 90791 | Psychiatric diagnostic evaluation | 164 | 163 | $16K |
| 87807 | 1,177 | 940 | $14K | |
| 97802 | 218 | 205 | $14K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | 201 | 183 | $13K |
| 96161 | 3,680 | 3,386 | $12K | |
| 90734 | 1,687 | 1,493 | $10K | |
| 99173 | 37,730 | 33,489 | $10K | |
| 97803 | 249 | 240 | $9K | |
| 90686 | 15,013 | 13,542 | $8K | |
| 90834 | Psychotherapy, 45 minutes with patient | 129 | 105 | $8K |
| 99050 | 355 | 327 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 195 | 159 | $7K |
| 95117 | 630 | 269 | $6K | |
| 80061 | Lipid panel | 359 | 322 | $5K |
| 99423 | 120 | 70 | $5K | |
| 90633 | 7,199 | 6,383 | $3K | |
| 90620 | 221 | 183 | $3K | |
| 0052A | 50 | 39 | $3K | |
| 99381 | 38 | 25 | $3K | |
| 0054A | 40 | 33 | $2K | |
| 0082A | 23 | 13 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 135 | 113 | $1K |
| 90670 | 18,370 | 15,427 | $1K | |
| 36415 | Collection of venous blood by venipuncture | 417 | 313 | $1K |
| 81003 | 436 | 388 | $988.16 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 68 | 48 | $917.97 |
| 0051A | 18 | 12 | $847.60 | |
| 0081A | 21 | 12 | $845.65 | |
| 90715 | 313 | 296 | $749.56 | |
| 90710 | 4,824 | 4,232 | $747.77 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 227 | 219 | $690.68 |
| 99177 | 1,458 | 1,306 | $548.81 | |
| 90723 | 13,622 | 11,687 | $373.99 | |
| 90461 | 13 | 13 | $214.50 | |
| 96160 | 56 | 56 | $213.11 | |
| 36416 | 8,935 | 6,541 | $197.50 | |
| 90647 | 12,955 | 11,233 | $112.20 | |
| 88720 | 19 | 14 | $104.78 | |
| 90656 | 1,109 | 1,054 | $97.94 | |
| 90680 | 9,779 | 8,441 | $90.61 | |
| 90696 | 484 | 422 | $58.08 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12 | 12 | $28.74 |
| 1159F | 54,558 | 47,339 | $1.76 | |
| 3078F | 12,999 | 11,726 | $0.00 | |
| 1160F | 32,419 | 29,513 | $0.00 | |
| 91300 | 115 | 84 | $0.00 | |
| 90700 | 276 | 241 | $0.00 | |
| 91308 | 115 | 69 | $0.00 | |
| 90685 | 13 | 12 | $0.00 | |
| 3074F | 13,496 | 12,180 | $0.00 | |
| 3008F | 4,979 | 4,808 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 52 | 44 | $0.00 |
| 91307 | 773 | 423 | $0.00 | |
| 91305 | 230 | 147 | $0.00 | |
| 3079F | 54 | 52 | $0.00 |